ARTIVA BIOTHERAPEUTICS INC (ARTV)
Health Care · Cell-based immunotherapy · NASDAQ
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
What ARTIVA BIOTHERAPEUTICS INC does
Artiva Biotherapeutics is an early-stage biotechnology company developing AlloNK, an allogeneic natural killer cell immunotherapy for cancer indications. The company is advancing clinical trials for its lead product candidate and seeking regulatory approval for its manufacturing facility in San Diego, California. Artiva is focused on research, development, and eventual commercialization of cell-based immunotherapies.
Themes: Cell therapy, Immunotherapy, Oncology, NK cell therapy
Fundamentals
- Price$10.93 as of 2026-08-21 close
- Market cap$534M as of 2026-08-21
- 1-year return+294.6% 2025-08-21 close $2.77 → 2026-08-21 close $10.93
- P/En/a negative earnings
- Net margin-26045.0% as of 2026-08-24
- ROE-60.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta5.50 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ARTV compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ARTIVA BIOTHERAPEUTICS INC looks technically
ARTIVA BIOTHERAPEUTICS INC (ARTV) is trading 56.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 202 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago. It is 24.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 56.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +56.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.12 | $10.12 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.97 | $6.97 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 12.27. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 202 trading days ago — a "golden cross", a bullish long-term signal | 202 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 23.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($10.40 to $12.27) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 28.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.53 | $14.53 |
|---|---|---|
| From the 52-week high | it is 24.8% below its 52-week high (its highest price of the past year) | -24.8% |
| Above the 52-week low | it is 392.3% above its 52-week low (its lowest price of the past year) | +392.3% |
| Below the 52-week high | it is 24.8% below its highest point of the past year | 24.8% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $17.31 (set on 2024-10-01) | $17.31 |
| Given back of the 52-week move | over the past year its closes ranged ($2.28 to $13.39), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.17 to $6.52. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.1% |
| From the all-time high | it is 36.9% below its all-time high | -36.9% |
| Nearest price level | it is trading 11.1% above a support level at $9.72 — a price it turned at four times since 2024-09-16, most recently on 2026-07-31. Since 2024-08-21 it has 10 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -11.1% |
| All-time low | its lowest closing price on record is $1.47 (set on 2025-06-27) | $1.47 |
| Above the all-time low | it is 643.5% above its all-time low | +643.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 88% of it) | 12th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8051 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8051 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.00 and $12.21 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.00 – $11.11 – $12.21 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 4.9 daily ranges above its 200-day average price (56.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.54× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 7.6% above the previous close 48 sessions ago and has not traded back through the level it left behind at 8 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.6% |
| Gap filled | a 3.9% gap up opened on 2026-07-24 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 20 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -6.58% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.0 percentage points (the stock gained 9.3% while the market gained 2.3%) | +7.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 33.7 percentage points (the stock gained 36.8% while the market gained 3.1%) | +33.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 122.5 percentage points (the stock gained 133.5% while the market gained 11.1%) | +122.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 274.1 percentage points (the stock gained 294.6% while the market gained 20.5%) | +274.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.4% of the share price. | +11.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $8.91 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +22.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.49 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -4.9% |
Price levels it has turned at before
ARTV last closed at $10.93 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.72 | Support | 11.1% below the last close | turned there four times · 2024-09-16 to 2026-07-31 |
| $12.29 | Resistance | 12.5% above the last close | turned there twice · 2024-09-09 to 2026-08-11 |
| $13.11 | Resistance | 19.9% above the last close | turned there three times · 2024-11-29 to 2026-05-06 |
| $8.47 | Support | 22.5% below the last close | turned there three times · 2026-04-29 to 2026-06-25 |
| $6.57 | Support | 39.9% below the last close | turned there twice · 2025-03-12 to 2026-06-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $12.27.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · beating the market · Most volatile (6%+ typical daily range) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$35.80 range $23.00 – $41.00; median $40.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ARTV
- Consensus EPS estimate-$0.534 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is currently unprofitable and faces substantial risks related to the clinical development, regulatory approval, and commercialization of its product candidates, particularly its lead candidate, AlloNK.","There is a significant need for additional capital to fund ongoing research, development, and clinical trial activities, and future financing may not be available on favorable terms or at all.","The company is dependent on the successful regulatory approval and operation of its in-house manufacturing facility in San Diego."]
Insider activity (SEC Form 4)
19 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days2 buys ($455726) · 1 sell ($5148) — 1 buying, 1 selling insiders
- Last 90 days19 buys ($18M) · 1 sell ($5148) — 1 buying, 1 selling insiders
- Last 180 days22 buys ($109M) · 6 sells ($482918) — 2 buying, 5 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ARTV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ARTV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 348,649
- Reported value $2,245,301
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 1 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ARTV had 1,921,843 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ARTV had 3.93% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.13 days to cover at the same settlement.
- Reported short interest (shares) 1,921,843
- Short interest (% of shares outstanding) 3.93%
- Prior settlement (shares) 1,724,074
- Reported change 11.47%
- Days to cover (reported) 5.13
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fate Therapeutics (FATE)
- Nkarta (NKTX)
- Century Therapeutics (IPSC)
- Caribou Biosciences (CRBU)
- Editas Medicine (EDIT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARTV vs…
ARTIVA BIOTHERAPEUTICS INC is found in…
Frequently asked questions
What does ARTIVA BIOTHERAPEUTICS INC (ARTV) do?
Artiva Biotherapeutics is an early-stage biotechnology company developing AlloNK, an allogeneic natural killer cell immunotherapy for cancer indications. The company is advancing clinical trials for its lead product candidate and seeking regulatory approval for its manufacturing facility in San Diego, California. Artiva is focused on research, development, and eventual commercialization of cell-based immunotherapies.
What sector is ARTIVA BIOTHERAPEUTICS INC (ARTV) in?
ARTIVA BIOTHERAPEUTICS INC (ARTV) is classified in the Health Care sector. Its industry is Cell-based immunotherapy. It trades on NASDAQ.
Who are ARTIVA BIOTHERAPEUTICS INC's (ARTV) competitors?
Notable peers of ARTIVA BIOTHERAPEUTICS INC (ARTV) include Fate Therapeutics, Nkarta, Century Therapeutics, Caribou Biosciences and Editas Medicine. This peer set is informational only — not financial advice.
Is ARTIVA BIOTHERAPEUTICS INC (ARTV) overbought or oversold right now?
ARTIVA BIOTHERAPEUTICS INC (ARTV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARTV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.